National Cancer Institute

The National Cancer Institute (NCI) coordinates the United States National Cancer Program and is part of the National Institutes of Health (NIH), which is one of eleven agencies that are part of the U.S. Department of Health and Human Services. The NCI conducts and supports research, training, health information dissemination, and other activities related to the causes, prevention, diagnosis, and treatment of cancer; the supportive care of cancer patients and their families; and cancer survivorship.

National Cancer Institute (NCI)
Agency overview
FormedAugust 5, 1937 (1937-08-05)
JurisdictionFederal government of the United States
HeadquartersOffice of the Director,
31 Center Drive, Building 31, Bethesda, Maryland,
Agency executive
Parent departmentUnited States Department of Health and Human Services
Parent agencyNational Institutes of Health
Child agencies

NCI is the oldest and has the largest budget and research program of the 27 institutes and centers of the NIH. It fulfills the majority of its mission via an extramural program that provides grants for cancer research. Additionally, the National Cancer Institute has intramural research programs in Bethesda, Maryland and at the Frederick National Laboratory for Cancer Research[6] at Fort Detrick, in Frederick, Maryland. The NCI receives more than US$5 billion in funding each year.[7]

The NCI supports a nationwide network of 71 NCI-designated Cancer Centers with a dedicated focus on cancer research and treatment[8] and maintains the National Clinical Trials Network.[9]



Anti-cancer drug investigations

Synthetic drugs

Hormones and steroids



The NCI is divided into several divisions and centers.[17]


  • Center for Cancer Research
The CCR includes approximately 250 internal NCI research groups in Frederick and Bethesda.[18]
  • Division of Cancer Epidemiology and Genetics
DCEG is divided into the Epidemiology and Biostatistics Program and the Human Genetics Program.[19]


  • Division of Cancer Biology
DCB oversees approximately 2000 grants per year in the areas of cancer cell biology; cancer immunology, hematology, and etiology; DNA and chromosome aberrations; structural biology and molecular applications; tumor biology and microenvironment; and tumor metastasis.[20] "Special Research Programs" falling under the aegis of the DCB include: Physical Sciences-Oncology Network, Cancer Systems Biology Consortium, Oncology Models Forum, Barrett's Esophagus Translational Research Network, New Approaches to Synthetic Lethality for Mutant KRAS-Dependent Cancers, Molecular and Cellular Characterization of Screen-Detected Lesions, Fusion Oncoproteins in Childhood Cancers, and Cancer Tissue Engineering Collaborative.[21]
  • Division of Cancer Control and Population Sciences
  • Division of Cancer Prevention
  • Division of Cancer Treatment and Diagnosis
DCTD supports eight research programs: The Biometric Research Program, The Cancer Diagnosis Program, The Cancer Imaging Program, The Cancer Therapy Evaluation Program, The Developmental Therapeutics Program, The Radiation Research Program, The Translational Research Program, and The Office of Cancer Complementary and Alternative Medicine.[22]
  • Division of Extramural Activities
DEA processes and supports the thousands of grant applications NCI receives each year and compiles reports on the progress of research funded by the NCI's programs.[23]

Office of the director

  • Center for Biomedical Informatics and Information Technology
  • Center for Cancer Genomics
CCG was created in 2011 and is responsible for management of The Cancer Genome Atlas and cancer genomics initiatives.
  • Center for Cancer Training
  • Center for Global Health
  • Center for Strategic Scientific Initiatives
In the 1990s, the Unconventional Innovation Program was created to integrate interdisciplinary technology research with biological applications. It was reorganized in 2004 as the CSSI.[24]
  • Center to Reduce Cancer Health Disparities
  • Center for Research Strategy
  • Coordinating Center for Clinical Trials
  • Technology Transfer Center


NCI-designated Cancer Centers

The NCI-designated Cancer Centers are one of the primary arms in the NCI's mission in supporting cancer research. There are currently 69 so-designated centers; 13 clinical cancer centers, 49 comprehensive cancer centers, and 7 basic laboratory cancer centers. NCI supports these centers with grant funding in the form of P30 Cancer Center Support Grants to support shared research resources and interdisciplinary programs. Additionally, faculty at the cancer centers receive approximately 75% of the grant funding awarded by the NCI to individual investigators.[8][25]

The NCI cancer centers program was introduced in 1971 with 15 participating institutions.[26]

National Clinical Trials Network

The NCTN was formed in 2014, from the Cooperative Group program to modernize the existing system to support precision medicine clinical trials. With precision medicine, a large number of patients must be screened to determine eligibility for treatments in development.

Lead Academic Participating Sites (LAPS) were chosen at 30 academic institutions for their ability to conduct clinical trials and screen a large number of participants and awarded grants to support the infrastructure and administration required for clinical trials. Most LAPS grant recipients are also NCI-designated cancer centers.[9] NCTN also stores surgical tissue from patients in a nationwide network of tissue banks at various universities.

Developmental Therapeutics Program

The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents.[27]

Under the label "Discovery & Development Services" several services are offered, among them the NCI-60 human cancer cell line screen and the Molecular Target Program.[28]

In the Molecular Target Program thousands of molecular targets have been measured in the NCI panel of 60 human tumor cell lines. Measurements include protein levels, RNA measurements, mutation status and enzyme activity levels.[29]

NCI-60 Human Tumor Cell Lines Screen

The evolution of strategies at the National Cancer Institute (NCI) illustrates the changes in screening that have resulted from advances in cancer biology. The Developmental Therapeutics Program (DTP) operates a tiered anti-cancer compound screening program with the goal of identifying novel chemical leads and biological mechanisms. The DTP screen is a three phase screen which includes: an initial screen which first involves a single dose cytotoxicity screen with the 60 cell line assay. Those passing certain thresholds are subjected to a 5 dose screen of the same 60 cell-line panel to determine a more detailed picture of the biological activity. A second phase screen establishes the maximum tolerable dosage and involves in vivo examination of tumor regression using the hollow fiber assay. The third phase of the study is the human tumor xenograft evaluation.

Active compounds are selected for testing based on several criteria: disease type specificity in the in vitro assay, unique structure, potency, and demonstration of a unique pattern of cellular cytotoxicity or cytostasis, indicating a unique mechanism of action or intracellular target.

A high correlation of cytotoxicity with compounds of known biological mechanism is often predictive of the drugs mechanism of action and thus a tool to aid in the drug development and testing. It also tells if there is any unique response of the drug which is not similar to any of the standard prototype compounds in the NCI database.


Carl Voegtlin[30]1938–1943
Roscoe Roy Spencer 1943–1947
Leonard Andrew Scheele1947–1948Served as the seventh Surgeon General of the United States from 1948 to 1956.
John Roderick Heller1948–1960
Kenneth Millo Endicott1960–1969
Carl Gwin Baker1970–1972
Frank Joesph Rauscher, Jr.1972–1976
Arthur Canfield Upton1977–1980
Vincent T. DeVita, Jr.1980–1988
Samuel Broder1988–1995
Richard D. Klausner1995–200111th Director, left to become President of the Case Institute of Health, Science, and Technology and later Executive Director of Global Health for the Bill & Melinda Gates Foundation.[31]
Andrew C. von Eschenbach2002–200612th Director, served from 2001 to 2006 before transitioning to a role as Commissioner of Food and Drugs.[32][33]
John E. Niederhuber2006–201013th Director of the NCI, was nominated by President George W. Bush.[34]
Harold Varmus2010–2015Co-winner of the Nobel Prize for studies of the genetic basis of cancer.[35] He was director of the National Institutes of Health from 1993 to 1999.
Norman E. SharplessOctober 2017–April 201915th Director of the NCI.[36][37]   Transitioned to acting Commissioner of Food and Drugs in April 2019.
Douglas R. Lowy (Acting)April 8, 2019 – Previously served as Acting Director April 2015 through October 2017. Serving as NCI's deputy director since September 2010.[38]

Notable NCI faculty

See also

Notes and references

  1. "Director's Page". National Cancer Institute. Retrieved 1 April 2015.
  2. "NCI Director Dr. Norman E. Sharpless—Director's Page—Leadership—About NCI". National Cancer Institute. 18 December 2018. Retrieved 1 January 2019.
  3. "Dr Norman Edward Sharpless, MD, NIH Enterprise Directory (NED)". Retrieved 2 January 2019.
  4. "Visitor Information". National Cancer Institute. 1980-01-01. Retrieved 2 January 2019.
  5. NCI's Shady Grove Campus To Open In 2013. NIH Record. LXII. 2 April 2010. Retrieved 2 January 2019. The change is being made primarily due to the leases expiring at EPN, EPS and a few other buildings on Executive Blvd. The new buildings would house, in one facility, staff from those leased sites... NCI will continue to occupy floors 10 and 11 of Bldg. 31’s A wing, as well as much of the 3rd floor, and the NCI director will remain in 31. There are also many staff members in lab buildings and the Clinical Center on campus and a large presence in Frederick at Ft. Detrick.
  6. "NCI-Frederick: NCI-Frederick Home Page". Retrieved 18 December 2011.
  7. "Funding Trends". National Cancer Institute. 2018-12-20.
  8. "NCI-Designated Cancer Centers". National Cancer Institute. Retrieved July 26, 2019.
  9. "NCI's National Clinical Trials Network". National Cancer Institute. 2014-05-29.
  10. "National Cancer Institute Act: Text of the Act of August 5, 1937, creating the National Cancer Institute and authorizing an appropriation therefor". JNCI Journal of the National Cancer Institute. 19 (2): 133–137. 1 August 1957. doi:10.1093/jnci/19.2.133. ISSN 0027-8874.
  11. "Statutes at Large Volume 50 (1937) Table of Contents; VOL. 49 – VOL. 51". Retrieved 1 January 2019.
  12. "75th Congress Public Law 244" (PDF). Retrieved 1 January 2019.
  13. "Statute 50 Page 559" (PDF). Retrieved 1 January 2019.
  14. December 13, 2016—Important Events in NCI History—National Cancer Institute (NCI). NIH Almanac. 18 October 2017. Retrieved 1 January 2019.
  15. Kaplan, Sheila (2019-03-12). "National Cancer Chief, Ned Sharpless, Named F.D.A.'s Acting Commissioner". The New York Times. ISSN 0362-4331. Retrieved 2019-12-04.
  16. Collins, Francis (November 1, 2019). "Statement on the return of Dr. Ned Sharpless as NCI Director". The NIH Director. Retrieved December 3, 2019.
  17. "NCI Organization". National Cancer Institute. 1980-01-01.
  18. "About CCR". 21 July 2014.
  19. "DCEG Home". Division of Cancer Epidemiology and Genetics – National Cancer Institute. 1980-01-01.
  20. "DCB Research Portfolio". National Cancer Institute. 2016-08-08.
  21. "Division of Cancer Biology". National Cancer Institute. 2016-08-08.
  22. "About DCTD – DCTD".
  23. "About NCI Division of Extramural Activities".
  24. "History – Center for Strategic Scientific Initiatives (CSSI)".
  25. "OCC Homepage – OCCWebApp 2.1.0".
  26. "History of the NCI Cancer Centers Program". National Cancer Institute. 2012-08-13.
  27. "Welcome to the Developmental Therapeutics Program". Developmental Therapeutics Program. National Cancer Institute. Retrieved 6 January 2018.
  28. "Discovery & Development Services". Developmental Therapeutics Program. National Cancer Institute. 26 August 2015. Retrieved 6 January 2018.
  29. "Molecular Targets". Developmental Therapeutics Program. National Cancer Institute. 12 May 2015. Retrieved 7 January 2018.
  30. "National Cancer Institute (NCI)". 7 July 2015.
  31. "Dr. Richard D. Klausner Named Executive Director of Global Health for Bill & Melinda Gates Foundation".
  32. U.S. Congress (7 December 2006). "Executive Session". Congressional Record. 152 (134): S11404–29, S11447–51. Retrieved 2006-12-12.
  33. "U.S. Senate: U.S. Senate Roll Call Votes 109th Congress – 2nd Session".
  34. "Emergent Biosolutions – Board of Directors bio". Retrieved 2013-12-06.
  35. "Director's Page – National Cancer Institute (Archive)". Archived from the original on 2015-03-31. Retrieved 2015-04-02.CS1 maint: BOT: original-url status unknown (link)
  36. "NCI Director Dr. Norman E. Sharpless—Director's Page—Leadership—About NCI". National Cancer Institute. 18 December 2018. Retrieved 1 January 2019.
  37. "Dr Norman Edward Sharpless, MD, NIH Enterprise Directory (NED)". Retrieved 2 January 2019.
  38. "NCI Deputy Director—Leadership—About US". National Cancer Institute. 14 August 2018. Retrieved 2 January 2019.

General references

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.